title: Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
abstract: The aim of this study was to estimate the diagnostic value of common application of CA 125 level measurement and 18F-FDG PET/CT examination in patients with a suspicion of recurrent ovarian cancer.
  
  
  METHODS
  A retrospective analysis was performed on a group of 68 patients aged 31-77 (average 57.7) with a suspicion of relapsing ovarian cancer who had CA 125 serum level measurement and PET/CT examination done with a maximum interval of 60 days.
  
  
  RESULTS
  PET/CT examination result was positive in 33 patients (48.5%) and negative in 35 (51.5%). Level of CA 125 was significantly higher in women with a positive PET/CT result than in patients with a negative one (average 199.9 U/ml and 15.7 U/ml, respectively, p < 0.001). Nevertheless, comparison of CA 125 level in groups defined according to the localization of the relapse showed no significant differences. Moreover, the ROC analysis revealed that the optimal cut-off point of CA 125 concentration to predict positive PET/CT result was 17.6 U/ml. Area under the curve was 0.91. Sensitivity, specificity and accuracy in prognosticating positive PET/CT result for the selected cut-off point of 17.6 U/ml were 90.9%, 80.0% and 85.3%, respectively.
  
  
  CONCLUSIONS
  CA 125 level does not depend on the localization of the recurrence. PET/CT is particularly useful in patients with a suspicion of relapsing ovarian cancer with CA 125 value of at least 17.6 U/ml.
authors.forename: M
authors.initials: M
authors.lastname: Fularz
authors.forename: P
authors.initials: P
authors.lastname: Adamiak
authors.affiliation: Rafał Czepczyński, M.D., Ph.D., Dept. of Endocrinology and Metabolism, Przybyszewskiego 49, PL-60-355 Poznan, Tel. +48/603 75 87 29, rafal.czepczynski@euromedic.pl.
authors.forename: R
authors.initials: R
authors.lastname: Czepczyński
authors.forename: G
authors.initials: G
authors.lastname: Jarząbek-Bielecka
authors.forename: A
authors.initials: A
authors.lastname: Rewers
authors.forename: W
authors.initials: W
authors.lastname: Kędzia
authors.forename: M
authors.initials: M
authors.lastname: Ruchała
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis*; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: 18F-FDG; CA 125; Ovarian cancer; PET/CT; diagnosis; recurrence